Administration of nivolumab plus ipilimumab: Infusion of the fixed‐ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma (CheckMate 742) and renal…

https://t.co/E72YhqSiph

RT @JournalCancer: There was no clinically relevant difference in safety between FRC and ASI as measured by the primary endpoint in either…

RT @JournalCancer: There was no clinically relevant difference in safety between FRC and ASI as measured by the primary endpoint in either…

There was no clinically relevant difference in safety between FRC and ASI as measured by the primary endpoint in either study; odds ratio (95% CI) of 0.87 (0.30–2.49) and 1.0 (0.30–3.39) for CheckMate 742 and CheckMate 800, respectively. https://t.co/Du…